GlassScriptPhysician profile
Lindsey Jackson
NPI 1598148819
$1,715.25
in general payments reported to CMS, 2019-2025
22 companies · $783 in 2025
The $783 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $392 · 2024: $540 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $380.20 | 2023-2025 | |
| Lilly USA, LLC | $342.40 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $148.53 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $109.50 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $108.64 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.75 | 2023-2025 | Xifaxan |
| Astellas Pharma US INC | $92.02 | 2024-2025 | Veozah |
| Axsome Therapeutics, INC. | $63.00 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $49.66 | 2023-2024 | Trintellix, Gattex |
| Exact Sciences Corporation | $45.66 | 2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $38.72 | 2024 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.25 | 2023-2024 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $36.11 | 2023-2024 | Otezla, Repatha |
| Gilead Sciences, INC. | $32.78 | 2025 | |
| Dexcom, INC. | $26.10 | 2025 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $17.17 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $15.62 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $14.57 | 2024 | Gardasil 9, Vaxelis, Gardasil |
| Astrazeneca Pharmaceuticals LP | $14.02 | 2025 | Breztri |
| Vbi Vaccine (Delaware) INC. | $13.25 | 2023 | Prehevbrio |
| Teva Pharmaceuticals USA, INC. | $13.21 | 2023 | Airduo Digihaler |
| Idorsia Pharmaceuticals US INC | $13.09 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.